Lexicon Pharmaceuticals is a biopharmaceutical company focused on finding breakthrough disease treatments. The company’s research team, using proprietary knockout gene technology, currently has five drug programs in mid-stage development for diabetes, glaucoma, rheumatoid arthritis, irritable bowel syndrome, and carcinoid syndrome.

The company today announced the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper will also appear in an upcoming print edition of the publication.

In the 4-week Phase 2a study described in the paper, 36 patients received once-daily oral administration of either a placebo or 150 milligrams or 300 milligrams of LX4211 in a randomized 1:1:1 fashion. Patients receiving LX4211 exhibited rapid and significant improvements relative to the placebo in multiple measures of glycemic control, including hemoglobal A1c, fasting plasma glucose, and oral glucose tolerance.

There were other positive results too. Additionally, serum triglycerides were significantly lower at the end of the 4-week treatment period and trends of meaningful reductions in body weight and blood pressure were observed. Importantly, LX4211 treatment demonstrated a favorable safety profile and was well tolerated in the studies.

Also described the paper was a subsequent clinical study conducted in poorly-controlled patients with type 2 diabetes. It showed that LX4211 treatment elevated levels of two gastrointestinal peptides, GLP-1 and PYY, known to be associated with enhanced metabolic control. It did so through inhibiting both SGLT1 and SGLT2.

For further information about Lexicon Pharmaceuticals, LX4211, and its other drug candidates, please visit the company’s website at www.lexpharma.com

Let us hear your thoughts below: